These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25195648)

  • 1. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
    Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
    Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
    Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
    J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
    Ha YE; Kang CI; Cha MK; Park SY; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2013 Nov; 42(5):403-9. PubMed ID: 24071027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study.
    Denis B; Lafaurie M; Donay JL; Fontaine JP; Oksenhendler E; Raffoux E; Hennequin C; Allez M; Socie G; Maziers N; Porcher R; Molina JM
    Int J Infect Dis; 2015 Oct; 39():1-6. PubMed ID: 26189774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia.
    Matsumura Y; Nagao M; Iguchi M; Yagi T; Komori T; Fujita N; Yamamoto M; Matsushima A; Takakura S; Ichiyama S
    Clin Microbiol Infect; 2013 Feb; 19(2):161-8. PubMed ID: 22332968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Kang CI; Song JH; Chung DR; Peck KR; Ko KS; Yeom JS; Ki HK; Son JS; Lee SS; Kim YS; Jung SI; Kim SW; Chang HH; Ryu SY; Kwon KT; Lee H; Moon C; Shin SY;
    Int J Antimicrob Agents; 2010 Sep; 36(3):284-7. PubMed ID: 20580534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
    Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
    Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
    Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
    To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
    Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
    Haruki Y; Hagiya H; Haruki M; Sugiyama T
    J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; Cueto Md; Gálvez J; Perea EJ; Pascual A
    Clin Microbiol Infect; 2008 Feb; 14(2):180-3. PubMed ID: 18005358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
    Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.